CME Group announced it has secured approval from the US antitrust regulator for its US$5.5 billion takeover of Michael Spencer’s NEX Group, moving the world’s biggest derivative exchange closer to securing a new avenue of growth, reported the Financial Times.
The US Department of Justice’s clearance, along with earlier approvals from other regulators in the United States, Germany, Italy, and Sweden, means that CME Group now has six approvals, with just the UK remaining. The exchange operator stated it was optimistic that it would win it soon.
If completed CME, the world’s largest futures exchange operator, will also be the dominant player in the US$500 billion a day market for US government debt.
The deal is now awaiting a formal ruling from the UK’s antitrust authorities, which is due on November 8.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas